ArticleOPEN ACCESS

The cardiometabolic safety of interleukin 23 versus interleukin 17 inhibitors in psoriasis: A large-scale global cohort study

Journal of the European Academy of Dermatology and Venereology
DOI: 10.1111/jdv.18830
6Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Kridin, K., Mruwat, N., Thaci, D., & Ludwig, R. J. (2023, May 1). The cardiometabolic safety of interleukin 23 versus interleukin 17 inhibitors in psoriasis: A large-scale global cohort study. Journal of the European Academy of Dermatology and Venereology. John Wiley and Sons Inc. https://doi.org/10.1111/jdv.18830

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free